Nexeon recognizes the value of establishing strong corporate partnerships. The company’s agreements with SurModics, Inc. and Unidym represent two collaborations formed to advance medical technology for the treatment of cardiovascular disease.

SurModics, Inc.

In July 2007 SurModics, Inc. and Nexeon announced the formation of a licensing agreement to collaborate on a novel stent system for the treatment of coronary artery disease. SurModics' proprietary Finale™ prohealing coating technology incorporates extracellular matrix (ECM) proteins designed to improve and accelerate tissue healing of implantable medical devices through the body’s own healing mechanisms. The stent system in development will incorporate this unique coating technology and Nexeon’s proprietary low-profile coronary stent system to address late stent thrombosis, a serious adverse event occurring in a small number of drug-eluting stent cases. The press release announcing this agreement may be found here.

SurModics is also an equity investor in Nexeon.

For more information please visit www.surmodics.com

Unidym, Inc.

In August 2007 Nexeon signed an agreement with Unidym, Inc., a subsidiary of Arrowhead Corporation, granting Nexeon exclusive license to use Unidym’s carbon nanotube technology to develop medical devices for the treatment of cardiovascular disease. Nexeon believes that the application of nanotechnology to interventional devices such as catheters and stents will change the rules under which device designers operate, allowing them to implement improvements not previously deemed possible. The combination of Unidym’s nanotechnology scientific expertise and patent position with Nexeon’s medical device development capabilities has positioned the company for leadership in this next wave of innovations. The press release announcing this agreement may be found here.

For more information please visit www.unidym.com

CAUTION – Investigational device. Limited by Federal (U.S.) law to investigational use.